Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 88,044

Document Document Title
WO/2018/014012A1
The invention provides immunostimulatory glycolipids and compositions thereof and methods of use thereof.  
WO/2018/014030A1
A method of making a capsule comprising a plurality of compartments, the method comprising: initiating extrusion of a filament solution through a filament extruder; laying the filament solution to form a base of the capsule; forming a fi...  
WO/2018/013534A1
The present invention relates to methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3Kbeta and anti-immune checkpoint agents.  
WO/2018/013589A1
Ex vivo cultures of cells having thymic function and methods of use and methods of making are disclosed.  
WO/2018/013559A1
The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of estrogen-related diseases and conditions.  
WO/2018/011375A1
The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammat...  
WO/2018/013142A1
Compositions and methods for topical treatment of hair loss in otherwise normal skin that is affected by alopecia are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activi...  
WO/2018/013870A1
Provided herein are combinations of (a) ceftibuten or a pharmaceutically acceptable salt thereof, or a hydrate of the foregoing; and (b) clavulanic acid, or a pharmaceutically acceptable salt thereof for use in a method of treating or pr...  
WO/2018/011588A1
There is herein provided pharmaceutical formulations and kits-of-parts comprising a β2- adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a β3- adrenergic receptor agonist, or a pharmaceutically acceptable...  
WO/2018/010624A1
A reversibly cross-linked biodegradable polymer vesicle with a positively charged internal membrane, and a preparation method and application for preparing an anti-tumor drug thereof. A tumor-targeting, reduction-sensitive reversibly cro...  
WO/2018/013568A1
The present invention includes a composition and method for the treatment of an eye disease comprising a therapeutically effective amount of an autophagy stimulator that treats or slows the progression of the eye disease by enhancing or ...  
WO/2018/011989A1
Provided is a graft material for treating nerve damage, the graft material including dental pulp cells, wherein properties required of dental pulp cells provided as a graft material for treating nerve damage are identified. The present i...  
WO/2018/012497A1
The present invention mainly addresses the problem of providing a novel and specific knockout model animal that presents a symptom of a disease accompanied by a synapse abnormality in the brain, a method for producing same, and a therape...  
WO/2018/013239A1
This disclosure provides combination therapies for treating cancers. In particular, this disclosure provides methods for treating non-Hodgkin lymphoma comprising administering a combination of a SYK inhibitor and a second therapeutic agent.  
WO/2018/013929A1
Provided herein are compositions and methods for improving immune system function. In particular, provided herein are compositions, methods, and uses of YY1 and EZH2 inhibitors for preventing and reversing T-cell exhaustion (e.g., for us...  
WO/2018/006750A1
Provided is a secretory protein sDSS1 of a higher primate. The protein can be detected in human blood serum and cerebrospinal fluid. The sDSS1 protein can bind, under non-enzymatic conditions, with an oxidized protein to form a polymer, ...  
WO/2018/007957A1
The present invention refers to novel thiazolo[5,4-d]pyrimidine derivatives that are inverse agonists of the adenosine A2A receptor, to a process for their preparation, to the pharmaceutical compositions containing them and to their use ...  
WO/2018/007788A1
A p38 MAPK inhibitor for use in the treatment or prevention of severe influenza in a human patient. In some embodiments, the severe influenza maybe characterised by hypercytokinemia involving elevated levels of one or more pro-inflammato...  
WO/2018/009916A1
The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via...  
WO/2018/008750A1
Provided are a method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and an agent for the prevention or treatment of diseases caused by interle...  
WO/2018/007554A1
The present invention relates to a pharmaceutical combination comprising: (a) vinflunine or a pharmaceutically acceptable salt thereof, and (b) at least one PD1 -inhibitor and/or at least one PD-L1 -inhibitor or pharmaceutically acceptab...  
WO/2018/008932A1
The present invention provides a composition for inhibiting the survival or growth of a tubercle bacillus, containing a material which induces the polarization of a macrophage into an MI macrophage, and a method for inhibiting the surviv...  
WO/2018/007920A1
An antagonist of Neurokinin-1 receptor (NKIR), or its ligand Substance P (SP), for use in the treatment of bacterial infections, in particular acute cystitis, or for the management of pain related to the bacterial infection. Compositions...  
WO/2018/007796A1
The present invention relates to a handheld vibrating mesh nebuliser for delivery of a medicament to the respiratory system in therapy. The present invention also relates to a supply container for loading the nebuliser with liquid medica...  
WO/2018/009500A1
Aspects of the present invention are directed to an oral dosage form comprising a core containing one more active ingredients and a fast-release exterior coating. The fast release exterior coating includes a water soluble polymer; a sacc...  
WO/2018/008973A1
The present invention relates to a composition comprising a Forsythiae Fructus extract as an effective ingredient for preventing, ameliorating or treating peripheral neuropathy, particularly chemotherapy-induced peripheral neuropathy (CI...  
WO/2018/009628A1
A method of screening is provided including providing a combination of a plurality of proliferating cell types wherein each proliferating cell type has a unique associated barcode within its genome that is different from other proliferat...  
WO/2018/009663A1
Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-y-lyase comprising one or more am...  
WO/2018/008470A1
Provided is an SIRPα-targeting antitumor agent which inhibits the binding of CD47 to SIRPα and exerts an improved antitumor effect. Also provided is an antitumor agent which is capable of more effectively exerting an antitumor effect w...  
WO/2018/008711A1
The present invention addresses the problem of discovering an effective cancer therapy method and providing a medicine. Provided is a medicine comprising a combination of a compound represented by general formula (I), a salt, solvate or ...  
WO/2018/007430A1
The invention relates to inhibitors of the host acetyl-CoA-carboxylase (ACC) for use in treating mycobacterial diseases and to pharmaceutical compositions containing such inhibitors for said use. The invention further relates to a kit of...  
WO/2018/001440A1
The present invention is related to baby love male capsules consisting of the following: - Active ingredients such as fludrocortisone, bumetanide, sodium bicarbonates, sodium chloride, and Licourice extract - Inactive ingredients such as...  
WO/2018/004871A1
Methods for inhibiting stenosis, obstruction and/or calcification of a heart valve following implantation in a vessel having a wall are disclosed. In one aspect the method includes providing a bioprosthetic heart valve mounted on an elas...  
WO/2018/004747A1
Methods of treating cancer or reducing the incidence of relapse of a cancer in a subject comprising co-administration of Toll-like receptor (TLR) 4 ligand, such as an HMGN1 protein, and a TLR 7 or 8 ligand, and optionally an immune check...  
WO/2018/005695A1
The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, in treating acute or chronic pruritus associated with a variety of medical conditions, including dermatitis/eczema, psoriasis, prurigo, urticaria,...  
WO/2018/001439A1
The present invention is related to a novel compressed tablet composition for helping in giving birth to females. The composition is named "Baby Love Female Tablets". The active ingredients comprised in the composition, according to the ...  
WO/2018/003817A1
A preventative and/or therapeutic agent for osteogenesis imperfecta, osteoporosis and/or osteoarthritis containing a peptide consisting of an amino acid sequence shown by (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu (SEQ ID NO: 1) or (b) Val-Asn-...  
WO/2018/002896A1
The present invention concerns pharmaceutical compositions comprising compounds with general formula I or poly-alkyl-bis- maltolic molecules and in particular derivatives of [(3-hydroxy-4- pyron-2-yl)methyl]-amine in combination with DNA...  
WO/2018/005234A1
The present invention provides a combination of an ERK1/2 inhibitor compound, 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin -4-yl}-5-[2-(morpholin- 4-yl) ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutical...  
WO/2018/005682A2
The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-Ll). In particular, the disclosed antibodies and fragments bind to human PD-Ll and comprise novel ...  
WO/2018/001232A1
The present invention relates to an acrylic acid-based derivative as represented by a general formula (I), stereoisomers and tautomers thereof, or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutica...  
WO/2018/001980A1
The present invention relates to a compound for use in a method for treating sepsis, severe sepsis or septic shock. The compound is selected from (2S)-2-amino-3-[4-(4- hydroxyphenoxy)-3,5-diiodo-phenyl]propanoic acid, and/or 3-[3,5-dibro...  
WO/2018/005444A2
Methods comprising administering and kits comprising a therapeutically effective amount of at least one first compound chosen from compounds having Formula A: and compounds having Formula B: prodrugs thereof, derivatives thereof, pharmac...  
WO/2018/004283A2
The present invention relates to a glucagon derivative, a conjugate thereof, a composition comprising the same and a use thereof and, more particularly, to a therapeutic use for the metabolic syndrome, hypoglycemia and concomitant hyperi...  
WO/2018/004498A1
The present invention provides a pharmaceutical composition comprising at least one NSAIA that selectively inhibits COX-2 in combination with at least one H2 receptor antagonist in a single unit pharmaceutical dosage form. Pharmaceutical...  
WO/2018/003583A1
The purpose of the present disclosure is to provide a heat sensitive sheet having an excellent wearing feeling both in an initial state and in use. This heat sensitive sheet has the following configuration. This heat sensitive sheet (1) ...  
WO/2018/005417A1
A method of stimulating platelet formation using a drug that stimulates mitochondrial biogenesis is described. The drug can be used to treat a subject that has been diagnosed with thrombocytopenia or a relatively low platelet count, or i...  
WO/2018/002153A1
The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to gammaherpesvi...  
WO/2018/003584A1
The purpose of the disclosure is to provide a warming sheet that does not tend to cause low-temperature burns and the fixing part of which does not tend to remain on clothing. The warming sheet of the disclosure has the following configu...  
WO/2017/222035A1
It becomes possible to induce cell death of cancer cells and inhibit cell proliferation of cancer cells. A medicinal agent capable of inhibiting both of GST-π and MRPL17 is contained as an active ingredient, or a medicinal agent capable...  

Matches 1 - 50 out of 88,044